Enhanced bioavailability of piroxicam using Gelucire 44/14 and Labrasol: in vitro and in vivo evaluation
- 18 September 2003
- journal article
- research article
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 56 (3), 453-459
- https://doi.org/10.1016/s0939-6411(03)00142-5
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Enhanced bioavailability of piroxicam using Gelucire 44/14 and Labrasol: in vitro and in vivo evaluationEuropean Journal of Pharmaceutics and Biopharmaceutics, 2003
- Improved dissolution behaviour of steam-granulated piroxicamEuropean Journal of Pharmaceutics and Biopharmaceutics, 2002
- Self-dispersing lipid formulations for improving oral absorption of lipophilic drugsEuropean Journal of Pharmaceutics and Biopharmaceutics, 2000
- Pharmacokinetic profile and adverse gastric effect of zinc-piroxicam in ratsGeneral Pharmacology: The Vascular System, 1999
- The Biopharmaceutics Classification System: Highlights of the FDA's Draft GuidanceDissolution Technologies, 1999
- Pharmacokinetic profile of piroxicam β-cyclodextrin, in rat plasma and lymphGeneral Pharmacology: The Vascular System, 1997
- Influence of lipolysis on drug absorption from the gastro-intestinal tractAdvanced Drug Delivery Reviews, 1997
- Lipid-based vehicles for the oral delivery of poorly water soluble drugsAdvanced Drug Delivery Reviews, 1997
- Dissolution kinetics of piroxicam in solid dispersions with polyethylene glycol 4000International Journal of Pharmaceutics, 1993
- The preparation of prolonged action formulations in the form of semi solid matrix into hard gelatin capsules of oxprenolol I. Thermocap methodDrug Development and Industrial Pharmacy, 1991